Abstract
Multiple myeloma (MM) is a haematologic malignancy with significant improvements in the overall survival over the last decade. However, patients still relapse and die due to a lack of treatment options. Ultimately, novel therapies with the potential for long term remissions are needed for patients with advanced MM. Research efforts for such immune therapies were not successful until recently when the first immunotherapies for MM were approved in 2015 and many more are under development. In this review, we focus on adoptive cell therapies including CAR T-cell and CAR NK-cell therapies for patients with MM. We will provide an update on clinical and translational advances with a focus on results from ongoing clinical trials with BCMA targeted cellular therapies and the development of other novel targets, changes in the manufacturing process, trials focusing on earlier lines of therapy and combinations with other therapies as well as off the shelf products.
Citations
May 30, 2020·Scandinavian Journal of Immunology·Deming Feng, Jian Sun
Sep 10, 2020·Hematological Oncology·Junji Tanaka
Jul 6, 2020·Cancer Immunology, Immunotherapy : CII·Tan-Huy ChuJe-Jung Lee
Sep 23, 2020·BMJ : British Medical Journal·Urvi A Shah, Sham Mailankody
Sep 27, 2020·Nature Reviews. Clinical Oncology·Lekha Mikkilineni, James N Kochenderfer
Nov 12, 2020·Journal of Clinical Medicine·Paula Rodríguez-OteroJesús F San Miguel
Feb 10, 2021·Cytotherapy·Junji Tanaka
Mar 27, 2021·Stem Cell Research & Therapy·Margaret G LambDean A Lee
Apr 18, 2021·Blood Reviews·Karthik RamasamyPaul Richardson
Apr 19, 2021·Annals of Hematology·Sini LuomaAnne Nihtinen
Jun 3, 2021·Cancers·Hiroko Nishida
Jul 3, 2021·Frontiers in Oncology·Gregorio BarilàRenato Zambello
Jul 27, 2021·Frontiers in Oncology·Alessandra RomanoNicola Giuliani
Jul 31, 2021·Current Opinion in Immunology·Edgar Meinl, Markus Krumbholz
Aug 14, 2021·Lancet·Dickran Kazandjian, Ola Landgren
Aug 26, 2021·Current Hematologic Malignancy Reports·Carlyn Rose Tan, Urvi A Shah
Jul 2, 2021·Haematologica·Leo RascheMarc S Raab